Top

Gepubliceerd in:

01-02-2013 | Artikelen

De amygdala, een schakelstation voor het aan- en uitzetten van pijn: de rol van limbisch corticotropin-releasing factor bij neuropathische pijn

Auteurs: Dr. Tom Rouwette, dr. Pascal Vanelderen, prof. dr. Eric Roubos, prof. dr. Tamás Kozicz, prof.dr. Kris Vissers

Gepubliceerd in: Neuropraxis | Uitgave 1/2013

Samenvatting

Corticotropin-releasing factor (CRF) is essentieel bij stressadaptatie en veroorzaakt fysiologische stressresponsen via de hypothalamus-hypofyse-bijnier-as (HHB-as), wat leidt tot een verscheidenheid aan gedragsveranderingen en autonome en endocriene effecten om fysiologische en mentale homeostase te waarborgen (Chrousos & Gold, 1992; Smagin & Dunn, 2000; Vale et al., 1981). Dit gebeurt doordat CRF als neurotransmitter en/of neuromodulator op het centrale zenuwstelsel (CZS) werkt, met de limbische bed-nucleus van de stria terminalis (BST) en de centrale amygdala (CeA) (Deyama et al., 2007; Ji & Neugebauer, 2008) als belangrijke inputgebieden. Door chronische pijn wordt het functioneren van de HHB-as vaak ontregeld. Hierdoor kunnen angststoornissen en depressie optreden, ziekten die regelmatig geassocieerd blijken met een verstoorde werking van limbisch CRF (Arborelius et al., 1999; Blackburn-Munro & Blackburn-Munro, 2001). Recent is de sterke link tussen pijnverwerking en CRF beschreven (Lariviere & Melzack, 2000) en bewijs voor de betrokkenheid van limbisch CRF bij nociceptieve gevoeligheid, ofwel de gewaarwording van pijn, tijdens neuropathische pijn neemt toe (Bomholt et al., 2005; Rouwette et al., 2012a; Ulrich-Lai et al., 2006). Dit review geeft een overzicht van uitkomsten uit recent onderzoek naar hersengebieden die betrokken zijn bij het optreden van neuropathische pijn, waarbij de nadruk ligt op de rol hierbij van CRF. De amygdala, een kern in de temporaalkwab die lijkt te kunnen schakelen tussen nociceptie en analgesie, wordt beschouwd als belangrijk hersengebied voor pijnverwerking.

vorige artikel Woorden Vooraf

volgende artikel Sekseverschillen in het effect op hippocampusvolume van de interactie tussen het serotoninetransportergenpolymorfisme en stressvolle gebeurtenissen in de kindertijd

Arborelius, L., Owens, M.J., Plotsky, P.M. & Nemeroff, C.B. (1999). The role of corticotropin-releasing factor in depression and anxiety disorders. Journal of Endocrinology, 160, 1-12.PubMedCrossRef

Argoff, C.E. (2007). The coexistence of neuropathic pain, sleep, and psychiatric disorders: a novel treatment approach. The Clinical Journal of Pain, 23, 15-22.PubMedCrossRef

Attal, N., Cruccu, G., Haanpaa, M., Hansson, P., Jensen, T.S., Nurmikko, T., Sampaio, C., Sindrup, S. & Wiffen, P. (2006). EFNS guidelines on pharmacological treatment of neuropathic pain. European Journal of Neurology, 13, 1153-1169.PubMedCrossRef

Bale, T.L. & Vale, W.W. (2004). CRF and CRF receptors: role in stress responsivity and other behaviors. Annual Review of Pharmacology and Toxicology, 44, 525-557.PubMedCrossRef

Binneman, B., Feltner, D., Kolluri, S., Shi, Y., Qiu, R. & Stiger, T. (2008). A 6-week randomized, placebo-controlled trial of CP-316,311 (a selective CRH1 antagonist) in the treatment of major depression. American Journal of Psychiatry, 165, 617-620.PubMedCrossRef

Blackburn-Munro, G. & Blackburn-Munro, R.E. (2001). Chronic pain, chronic stress and depression: coincidence or consequence? Journal of Neuroendocrinology, 13, 1009-1023.PubMedCrossRef

Bomholt, S.F., Mikkelsen, J.D. & Blackburn-Munro, G. (2005). Normal hypothalamo-pituitary-adrenal axis function in a rat model of peripheral neuropathic pain. Brain Research, 1044, 216-226.PubMedCrossRef

Bourbia, N., Ansah, O.B. & Pertovaara, A. (2010). Corticotropin- releasing factor in the rat amygdala differentially influences sensorydiscriminative and emotional-like pain response in peripheral neuropathy. Journal of Pain, 11, 1461-1471.PubMedCrossRef

Chrousos, G.P. & Gold, P.W. (1992). The concepts of stress and stress system disorders. Overview of physical and behavioral homeostasis. Journal ofthe American Medical Association, 267, 1244-1252.CrossRef

Coric, V., Feldman, H.H., Oren, D.A., Shekhar, A., Pultz, J., Dockens, R.C., Wu, X., Gentile, K.A., Huang, S.P., Emison, E., Delmonte, T., D'Souza, B.B., Zimbroff, D.L., Grebb, J.A., Goddard, A.W. & Stock, E.G. (2010). Multicenter, randomized, double-blind, active comparator and placebo-controlled trial of a corticotropin-releasing factor receptor-1 antagonist in generalized anxiety disorder. Depression and Anxiety, 27, 417-425.PubMedCrossRef

Cui, X.Y., Lundeberg, T. & Yu, L.C. (2004). Role of corticotropin-releasing factor and its receptor in nociceptive modulation in the central nucleus of amygdala in rats. Brain Research, 995, 23-28.PubMedCrossRef

Deyama, S., Nakagawa, T., Kaneko, S., Uehara, T. & Minami, M. (2007). Involvement of the bed nucleus of the stria terminalis in the negative affective component of visceral and somatic pain in rats. Behavioural Brain Research, 176, 367-371.PubMedCrossRef

Dharmshaktu, P., Tayal, V., Kalra, B.S. (2012). Efficacy of Antidepressants as Analgesics: A Review. Journal of Clinical Pharmacology, 52, 6-17.PubMedCrossRef

Dong, H.W., Petrovich, G.D., Watts, A.G. & Swanson, L.W. (2001). Basic organization of projections from the oval and fusiform nuclei of the bed nuclei of the stria terminalis in adult rat brain.Journal of Comparative Neurology, 436, 430-455.PubMedCrossRef

Dworkin, R.H., O'Connor, A.B., Backonja, M., Farrar, J.T., Finnerup, N.B., Jensen, T.S., Kalso, E.A., Loeser, J.D., Miaskowski, C., Nurmikko, T.J., Portenoy, R.K., Rice, A.S., Stacey, B.R., Treede, R.D., Turk, D.C. & Wallace, M.S. (2007). Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain, 132, 237-251.PubMedCrossRef

Freynhagen, R., Baron, R., Gockel, U. & Tolle, T.R. (2006). painDETECT: a new screening questionnaire to identify neuropathic components in patients with back pain. Current Medical Research and Opinion, 22, 1911-1920.PubMedCrossRef

Hu, B., Doods, H., Treede, R.D. & Ceci, A. (2009). Depression-like behaviour in rats with mononeuropathy is reduced by the CB2- selective agonist GW405833. Pain, 143, 206-212.PubMedCrossRef

Hummel, M., Cummons, T., Lu, P., Mark, L., Harrison, J.E., Kennedy, J.D. & Whiteside, G.T. (2010). Pain is a salient "stressor" that is mediated by corticotropin-releasing factor-1 receptors. Neuropharmacology, 59, 160-166.PubMedCrossRef

Hunt, S.P. & Mantyh, P.W. (2001). The molecular dynamics of pain control. Nature Reviews Neuroscience, 2, 83-91.PubMedCrossRef

Ji, G. & Neugebauer, V. (2008). Pro- and anti-nociceptive effects of corticotropin-releasing factor (CRF) in central amygdala neurons are mediated through different receptors.Journal of Neurophysiology, 99, 1201-1212.PubMedCrossRef

Ji, G., Fu, Y., Ruppert, K.A. & Neugebauer, V. (2007). Pain-related anxiety-like behavior requires CRF1 receptors in the amygdala. Molecular Pain, 3, 13.PubMedCrossRef

Kasckow, J.W., Regmi, A., Gill, P.S., Parkes, D.G. & Geracioti, T.D.(1997). Regulation of corticotropin-releasing factor (CRF) messenger ribonucleic acid and CRF peptide in the amygdala: studies in primary amygdalar cultures. Endocrinology, 138, 4774-4782.PubMedCrossRef

Kloet, E.R. de, Joels, M. & Holsboer, F. (2005). Stress and the brain: from adaptation to disease. Nature Reviews Neuroscience, 6, 463-75.PubMedCrossRef

Knapp, D.J., Whitman, B.A., Wills, T.A., Angel, R.A., Overstreet, D.H., Criswell, H.E., Ming, Z. & Breese, G.R. (2011). Cytokine involvement in stress may depend on corticotrophin releasing factor to sensitize ethanol withdrawal anxiety. Brain, Behavior and Immunity, 25, Suppl 1, S146-54.CrossRef

Kozicz, T., Bittencourt, J.C., May, P.J., Reiner, A., Gamlin, P.D., Palkovits, M., Horn, A.K., Toledo, C.A. & Ryabinin, A.E. (2011). The EdingerWestphal nucleus: a historical, structural, and functional perspective on a dichotomous terminology.Journal of Comparative Neurology, 519,1413-1434.PubMedCrossRef

Lariviere, W.R. & Melzack, R. (2000). The role of corticotropin-releasing factor in pain and analgesia. Pain, 84, 1-12.PubMedCrossRef

Lariviere, W.R., Fiorenzani, P., Ceccarelli, I., Massafra, C., Sorda, G., Di Canio, C. & Aloisi, A.M. (2011). Central CRH administration changes formalin pain responses in male and female rats. Brain Research, 1383, 128-134.PubMedCrossRef

Leung, L. & Cahill, C.M. (2010). TNF-alpha and neuropathic pain–a review.Journal of Neuroinflammation, 7, 27.PubMedCrossRef

Manas, A., Monroy, J.L., Ramos, A.A., Cano, C., Lopez-Gomez, V., Masramon, X. & Perez, M. (2011). Prevalence of Neuropathic Pain in Radiotherapy Oncology Units. International Journal of Radiation Oncology Biology Physics, 81, 511-520CrossRef

Millan, M.J. 2002. Descending control of pain. Progress in Neurobiology, 66, 355-474.PubMedCrossRef

Raber, J., Koob, G.F. & Bloom, F.E. (1995). Interleukin-2 (IL-2) induces corticotropin-releasing factor (CRF) release from the amygdala and involves a nitric oxide-mediated signaling; comparison with the hypothalamic response.Journal of Pharmacology and Experimental Therapeutics, 272, 815-824.

Regev, L., Neufeld-Cohen, A., Tsoory, M., Kuperman, Y., Getselter, D., Gil, S. & Chen, A. (2011). Prolonged and site-specific overexpression of corticotropin-releasing factor reveals differential roles for extended amygdala nuclei in emotional regulation. Molecular Psychiatry, 16, 714-728PubMedCrossRef

Ro, L.S. & Chang, K.H. (2005). Neuropathic pain: mechanisms and treatments. Chang Gung Medical Journal, 28, 597-605.PubMed

Roeska, K., Doods, H., Arndt, K., Treede, R.D. & Ceci, A. (2008). Anxiety-like behaviour in rats with mononeuropathy is reduced by the analgesic drugs morphine and gabapentin. Pain, 139, 349-357.PubMedCrossRef

Rouwette, T., Klemann, K., Gaszner, B., Scheffer, G.J., Roubos, E.W., Scheenen, W.J, Vissers, K. & Kozicz, T. (2011). Differential responses of corticotropin-releasing factor and urocortin 1 to acute pain stress in the rat brain. Neuroscience, 183, 15-24.PubMedCrossRef

Rouwette, T., Vanelderen, P., Reus, M.D., Loohuis, N.O., Giele, J., Egmond, J.V., Scheenen, W., Scheffer, G.J., Roubos, E., Vissers, K. & Kozicz, T. (2012a). Experimental neuropathy increases limbic forebrain CRF. European Journal of Pain, 16, 61-71.CrossRef

Rouwette, T., Vanelderen, P., Roubos, E.W., Kozicz, T. & Vissers, K.C. (2012b). The amygdala, a relay station for switching pain on and off. European Journal of Pain, 16, 782-792.CrossRef

Sherbourne, C.D., Asch, S.M., Shugarman, L.R., Goebel, J.R., Lanto, A.B., Rubenstein, L.V., Wen, L., Zubkoff, L., & Lorenz, K.A. (2009). Early identification of co-occurring pain, depression and anxiety. Journal of General Internal Medicine, 24, 620-625.PubMedCrossRef

Smagin, G.N. & Dunn, A.J. (2000). The role of CRF receptor subtypes in stress-induced behavioural responses. European Journal of Pharmacology, 405, 199-206.PubMedCrossRef

Treede, R.D., Jensen, T.S., Campbell, J.N., Cruccu, G., Dostrovsky, J.O., Griffin, J.W., Hansson, P., Hughes, R., Nurmikko, T. & Serra, J. (2008). Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurology, 70, 1630-1635.PubMedCrossRef

Ulrich-Lai, Y.M., Xie, W., Meij, J.T., Dolgas, C.M., Yu, L. & Herman, J.P. (2006). Limbic and HPA axis function in an animal model of chronic neuropathic pain. Physiology & Behavior, 88, 67-76.CrossRef

Vale, W., Spiess, J., Rivier, C. & Rivier, J. (1981). Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin. Science, 213, 1394-1397.PubMedCrossRef

Vissers, K.C. (2006). The clinical challenge of chronic neuropathic pain. Disability and Rehabilitation, 28, 343-349.PubMedCrossRef

Vit, J.P., Clauw, D.J., Moallem, T., Boudah, A., Ohara, P.T. & Jasmin, L. (2006). Analgesia and hyperalgesia from CRF receptor modulation in the central nervous system of Fischer and Lewis rats. Pain, 121, 241-260.PubMedCrossRef

Wittmann, G., Fuzesi, T., Singru, P.S., Liposits, Z., Lechan, R.M. & Fekete, C. (2009). Efferent projections of thyrotropin-releasing hormone-synthesizing neurons residing in the anterior parvocellular subdivision of the hypothalamic paraventricular nucleus.Journal of Comparative Neurology, 515, 313-330.PubMed

Zorrilla, E.P. & Koob, G.F. (2004). The therapeutic potential of CRF1 antagonists for anxiety. Expert Opinion on Investigational Drugs, 13, 799-828.PubMedCrossRef

Zorrilla, E.P. & Koob, G.F. (2010). Progress in corticotropin-releasing factor-1 antagonist development. Drug Discovery Today, 15, 371-383.PubMedCrossRef

Titel: De amygdala, een schakelstation voor het aan- en uitzetten van pijn: de rol van limbisch corticotropin-releasing factor bij neuropathische pijn
Auteurs: Dr. Tom Rouwette
dr. Pascal Vanelderen
prof. dr. Eric Roubos
prof. dr. Tamás Kozicz
prof.dr. Kris Vissers
Publicatiedatum: 01-02-2013
Uitgeverij: Bohn Stafleu van Loghum
Gepubliceerd in: Neuropraxis / Uitgave 1/2013
Print ISSN: 1387-5817
Elektronisch ISSN: 1876-5785
DOI: https://doi.org/10.1007/s12474-013-0002-3

Bohn Stafleu van Loghum

Deel dit onderdeel of sectie (kopieer de link)

Samenvatting

Log in om toegang te krijgen

Andere artikelen Uitgave 1/2013

Sekseverschillen in het effect op hippocampusvolume van de interactie tussen het serotoninetransportergenpolymorfisme en stressvolle gebeurtenissen in de kindertijd

De kinderschoenen ontgroeid

Neurologische symptomen in het perspectief van een verspreide representatie van vrije wil

Woorden Vooraf

Signalement